

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Equality impact assessment – Scoping**

**Rozanolixizumab for treating antibody-positive myasthenia gravis [ID5092]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Patient groups commented that it is important to ensure that no patient has to travel excessive distances to receive the treatment given the level of disability that many will face.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The geographical location of treatment centres is not an equalities issue that is within the remit of the committee. However, the committee can consider the frequency and method of treatment dosing and the associated impact on equalities.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

**Approved by Associate Director (name):** ...Linda Landells

**Date:** 12 December 2023